Emerald Advisers LLC Has $18.41 Million Holdings in Savara Inc. $SVRA

Emerald Advisers LLC trimmed its position in Savara Inc. (NASDAQ:SVRA) by 3.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 3,371,285 shares of the company’s stock after selling 124,211 shares during the period. Emerald Advisers LLC’s holdings in Savara were worth $18,407,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares during the last quarter. Principal Financial Group Inc. bought a new position in shares of Savara in the first quarter worth about $57,000. Russell Investments Group Ltd. boosted its position in Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the last quarter. Xponance LLC bought a new position in Savara in the fourth quarter valued at about $66,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Savara during the 3rd quarter worth approximately $44,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Price Performance

Savara stock opened at $5.74 on Tuesday. The stock has a 50-day moving average price of $5.45 and a two-hundred day moving average price of $5.55. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.18 billion, a PE ratio of -10.25 and a beta of 0.24. Savara Inc. has a 12 month low of $2.25 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Analysts expect that Savara Inc. will post -0.57 EPS for the current year.

Wall Street Analyst Weigh In

SVRA has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th. William Blair set a $10.00 price target on shares of Savara in a research report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Oppenheimer initiated coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $10.14.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.